SUMMARY An open study was designed primarily to evaluate the efficacy of rosoxacin in the treatment of gonorrhoea caused by penicillinase producing Neisseria gonorrhoeae (PPNG) and non-PPNG strains. A total of 199 patients (99 men and 100 women) satisfactorily completed follow up examinations, 50 men and 50 women having received rosoxacin 300 mg orally and the remainder having received kanamycin 2 g intramuscularly. Rosoxacin achieved an overall cure rate of 94% (96-7% for PPNG and 9007 for non-PPNG strains). In patients treated with kanamycin the overall cure rate was 8999% (92-7% for PPNG and 83' 3% for non-PPNG strains). A correlation between treatment failures and minimum inhibitory concentrations (MICs) of rosoxacin was noted in non-PPNG strains but not in PPNG strains. Side effects which were mild and self limiting were noted in 15 of 100 patients treated with rosoxacin. The high failure rates associated with non-PPNG strains requiring MICs of 0 125 mg/l and the observation of a substantial rise in the MICs for isolates after treatment is of concern. Otherwise, rosoxacin in a single dose of 300 mg appears to be safe and effective for the treatment of uncomplicated gonorrhoea.
Introduction
Gonococcal strains, especially those in the Far East, have been able to develop increasing levels of resistance to penicillin. This has been further complicated by the emergence of penicillinase producing Neisseria gonorrhoeae (PPNG) strains, which were first isolated in Singapore in 1976. Since then PPNG strains have become endemic, and in 1982 accounted for 2413 cases or 34-5% of all gonococcal isolates in Singapore. Like many countries in the Far East, Singapore has witnessed increasing failure rates with penicillin, and there is a constant need to evaluate new antimicrobials.
Rosoxacin is a quinolone antimicrobial agent structurally related to nalidixic acid. In vitro tests have confirmed that rosoxacin has potent activity against a broad spectrum of Gram negative bacteria including N gonorrhoeae. It is well absorbed by the oral route, with serum concentrations reaching 6 One observation which caused some concern was a significant rise in the MIC for isolates obtained after treatment from two patients whose treatment had failed. All patients whose treatment failed were interviewed again and although we cannot absolutely exclude the possibility of reinfection, we felt it was unlikely for the following reasons. The first follow up test was performed only 72 hours after treatment. Secondly, the patients were interviewed again and reminded of the objectives of this study and the importance of truthfulness, and we therefore have no reason to doubt their word. We were not, however, able to serotype the strains and therefore it was impossible to ascertain whether the increase in MIC represented selection of more resistant clones or induction of resistance. The possible mechanism should be investigated.
In conclusion, the use of rosoxacin may be considered in areas where PPNG strains are prevalent, but its use should be limited to centres with good follow up facilities.
